Skip to main content
Erschienen in: European Radiology 10/2018

02.05.2018 | Neuro

Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma

verfasst von: Eun Kyoung Hong, Seung Hong Choi, Dong Jae Shin, Sang Won Jo, Roh-Eul Yoo, Koung Mi Kang, Tae Jin Yun, Ji-Hoon Kim, Chul-Ho Sohn, Sung-Hye Park, Jae-Kyung Won, Tae Min Kim, Chul-Kee Park, Il Han Kim, Soon Tae Lee

Erschienen in: European Radiology | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To assess the association between MR imaging features and major genomic profiles in glioblastoma.

Methods

Qualitative and quantitative imaging features such as volumetrics and histogram analysis from normalised CBV (nCBV) and ADC (nADC) were evaluated based on both T2WI and CET1WI. The imaging parameters of different genetic profile groups were compared and regression analyses were used for identifying imaging-molecular associations. Progression-free survival (PFS) was analysed by a Kaplan-Meier test and Cox proportional hazards model.

Results

An IDH mutation was observed in 18/176 patients, and ATRX loss was positive in 17/158 of the IDH-wt cases. The IDH-mut group showed a larger volume on T2WI and a higher volume ratio between T2WI and CET1WI than the IDH-wt group (p < 0.05). In the IDH-mut group, higher mean nADC values were observed compared with the IDH-wt tumours (p < 0.05). Among the IDH-wt tumours, IDH-wt, ATRX-loss tumours revealed higher 5th percentile nADC values than the IDH-wt, ATRX-noloss tumours (p = 0.03). PFS was the longest in the IDH-mut group, followed by the IDH-wt, ATRX-loss groups and the IDH-wt, ATRX-noloss groups, consecutively (p < 0.05). We found significant associations of PFS with the genetic profiles and imaging parameters.

Conclusion

Major genetic profiles of glioblastoma showed a significant association with MR imaging features, along with some genetic profiles, which are independent prognostic parameters for GBM.

Key Points

• Significant correlation exists between radiological parameters such as volumetric and ADC values and major genomic profiles such as IDH mutation and ATRX loss status
• Radiological parameters such as the ADC value were feasible predictors of glioblastoma patients’ prognosis
• Imaging features can predict major genomic profiles of the tumours and the prognosis of glioblastoma patients
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Vigneswaran K, Neill S, Hadjipanayis CG (2015) Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med 3:95PubMedPubMedCentral Vigneswaran K, Neill S, Hadjipanayis CG (2015) Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med 3:95PubMedPubMedCentral
2.
Zurück zum Zitat Zinn PO, Sathyan P, Mahajan B et al (2012) A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature. PLoS One 7:e41522CrossRef Zinn PO, Sathyan P, Mahajan B et al (2012) A novel volume-age-KPS (VAK) glioblastoma classification identifies a prognostic cognate microRNA-gene signature. PLoS One 7:e41522CrossRef
3.
Zurück zum Zitat Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110CrossRef Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110CrossRef
4.
Zurück zum Zitat Cancer Genome Atlas Research N (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068CrossRef Cancer Genome Atlas Research N (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068CrossRef
5.
Zurück zum Zitat Belden CJ, Valdes PA, Ran C et al (2011) Genetics of glioblastoma: a window into its imaging and histopathologic variability. Radiographics 31:1717–1740CrossRef Belden CJ, Valdes PA, Ran C et al (2011) Genetics of glioblastoma: a window into its imaging and histopathologic variability. Radiographics 31:1717–1740CrossRef
6.
Zurück zum Zitat Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812CrossRef Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812CrossRef
7.
Zurück zum Zitat Frattini V, Trifonov V, Chan JM et al (2013) The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 45:1141–1149CrossRef Frattini V, Trifonov V, Chan JM et al (2013) The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 45:1141–1149CrossRef
8.
Zurück zum Zitat Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRef Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRef
9.
Zurück zum Zitat Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154CrossRef Sanson M, Marie Y, Paris S et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150–4154CrossRef
10.
Zurück zum Zitat Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRef Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRef
11.
Zurück zum Zitat Aldape K, Burger PC, Perry A (2007) Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 131:242–251PubMed Aldape K, Burger PC, Perry A (2007) Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 131:242–251PubMed
12.
Zurück zum Zitat Hill C, Hunter SB, Brat DJ (2003) Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol 10:212–217CrossRef Hill C, Hunter SB, Brat DJ (2003) Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol 10:212–217CrossRef
13.
Zurück zum Zitat Jiao Y, Killela PJ, Reitman ZJ et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722CrossRef Jiao Y, Killela PJ, Reitman ZJ et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722CrossRef
14.
Zurück zum Zitat Kannan K, Inagaki A, Silber J et al (2012) Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3:1194–1203CrossRef Kannan K, Inagaki A, Silber J et al (2012) Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3:1194–1203CrossRef
15.
Zurück zum Zitat Reuss DE, Sahm F, Schrimpf D et al (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146CrossRef Reuss DE, Sahm F, Schrimpf D et al (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146CrossRef
16.
Zurück zum Zitat Koschmann C, Calinescu AA, Nunez FJ et al (2016) ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Sci Transl Med 8:328ra328CrossRef Koschmann C, Calinescu AA, Nunez FJ et al (2016) ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Sci Transl Med 8:328ra328CrossRef
17.
Zurück zum Zitat Wiestler B, Capper D, Holland-Letz T et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451CrossRef Wiestler B, Capper D, Holland-Letz T et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451CrossRef
18.
Zurück zum Zitat Zinn PO, Colen RR (2013) Imaging genomic mapping in glioblastoma. Neurosurgery 60 Suppl 1:126–130CrossRef Zinn PO, Colen RR (2013) Imaging genomic mapping in glioblastoma. Neurosurgery 60 Suppl 1:126–130CrossRef
19.
Zurück zum Zitat Rees JH, Smirniotopoulos JG, Jones RV, Wong K (1996) Glioblastoma multiforme: radiologic-pathologic correlation. Radiographics 16:1413–1438 quiz 1462-1413CrossRef Rees JH, Smirniotopoulos JG, Jones RV, Wong K (1996) Glioblastoma multiforme: radiologic-pathologic correlation. Radiographics 16:1413–1438 quiz 1462-1413CrossRef
20.
Zurück zum Zitat Pope WB, Chen JH, Dong J et al (2008) Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology 249:268–277CrossRef Pope WB, Chen JH, Dong J et al (2008) Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology 249:268–277CrossRef
21.
Zurück zum Zitat Diehn M, Nardini C, Wang DS et al (2008) Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A 105:5213–5218CrossRef Diehn M, Nardini C, Wang DS et al (2008) Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A 105:5213–5218CrossRef
22.
Zurück zum Zitat Zinn PO, Mahmood Z, Elbanan MG, Colen RR (2015) Imaging genomics in gliomas. Cancer J 21:225–234CrossRef Zinn PO, Mahmood Z, Elbanan MG, Colen RR (2015) Imaging genomics in gliomas. Cancer J 21:225–234CrossRef
23.
Zurück zum Zitat Moton S, Elbanan M, Zinn PO, Colen RR (2015) Imaging genomics of glioblastoma: Biology, biomarkers, and breakthroughs. Top Magn Reson Imaging 24:155–163CrossRef Moton S, Elbanan M, Zinn PO, Colen RR (2015) Imaging genomics of glioblastoma: Biology, biomarkers, and breakthroughs. Top Magn Reson Imaging 24:155–163CrossRef
24.
Zurück zum Zitat Jamshidi N, Diehn M, Bredel M, Kuo MD (2014) Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. Radiology 270:1–2CrossRef Jamshidi N, Diehn M, Bredel M, Kuo MD (2014) Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation. Radiology 270:1–2CrossRef
25.
Zurück zum Zitat Gevaert O, Mitchell LA, Achrol AS et al (2014) Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. Radiology 273:168–174CrossRef Gevaert O, Mitchell LA, Achrol AS et al (2014) Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. Radiology 273:168–174CrossRef
26.
Zurück zum Zitat Gutman DA, Cooper LA, Hwang SN et al (2013) MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 267:560–569CrossRef Gutman DA, Cooper LA, Hwang SN et al (2013) MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 267:560–569CrossRef
27.
Zurück zum Zitat Wilson TA, Karajannis MA, Harter DH (2014) Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int 5:64CrossRef Wilson TA, Karajannis MA, Harter DH (2014) Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int 5:64CrossRef
28.
Zurück zum Zitat Joe BN, Fukui MB, Meltzer CC et al (1999) Brain tumor volume measurement: comparison of manual and semiautomated methods. Radiology 212:811–816CrossRef Joe BN, Fukui MB, Meltzer CC et al (1999) Brain tumor volume measurement: comparison of manual and semiautomated methods. Radiology 212:811–816CrossRef
29.
Zurück zum Zitat Busing KA, Kilian AK, Schaible T, Debus A, Weiss C, Neff KW (2008) Reliability and validity of MR image lung volume measurement in fetuses with congenital diaphragmatic hernia and in vitro lung models. Radiology 246:553–561CrossRef Busing KA, Kilian AK, Schaible T, Debus A, Weiss C, Neff KW (2008) Reliability and validity of MR image lung volume measurement in fetuses with congenital diaphragmatic hernia and in vitro lung models. Radiology 246:553–561CrossRef
30.
Zurück zum Zitat Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820CrossRef Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820CrossRef
31.
Zurück zum Zitat Carrillo JA, Lai A, Nghiemphu PL et al (2012) Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 33:1349–1355CrossRef Carrillo JA, Lai A, Nghiemphu PL et al (2012) Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 33:1349–1355CrossRef
32.
Zurück zum Zitat Metellus P, Coulibaly B, Colin C et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719–729CrossRef Metellus P, Coulibaly B, Colin C et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120:719–729CrossRef
33.
Zurück zum Zitat Higano S, Yun X, Kumabe T et al (2006) Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 241:839–846CrossRef Higano S, Yun X, Kumabe T et al (2006) Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 241:839–846CrossRef
34.
Zurück zum Zitat Kickingereder P, Sahm F, Radbruch A et al (2015) IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep 5:16238CrossRef Kickingereder P, Sahm F, Radbruch A et al (2015) IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep 5:16238CrossRef
35.
Zurück zum Zitat Xing Z, Yang X, She D, Lin Y, Zhang Y, Cao D (2017) Noninvasive assessment of IDH mutational status in World Health Organization grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging. AJNR Am J Neuroradiol 38:1138–1144CrossRef Xing Z, Yang X, She D, Lin Y, Zhang Y, Cao D (2017) Noninvasive assessment of IDH mutational status in World Health Organization grade II and III astrocytomas using DWI and DSC-PWI combined with conventional MR imaging. AJNR Am J Neuroradiol 38:1138–1144CrossRef
36.
Zurück zum Zitat Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002–6007CrossRef Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002–6007CrossRef
37.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRef Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRef
38.
Zurück zum Zitat Zhang K, Wang XQ, Zhou B, Zhang L (2013) The prognostic value of MGMT promoter methylation in glioblastoma multiforme: a meta-analysis. Fam Cancer 12:449–458CrossRef Zhang K, Wang XQ, Zhou B, Zhang L (2013) The prognostic value of MGMT promoter methylation in glioblastoma multiforme: a meta-analysis. Fam Cancer 12:449–458CrossRef
Metadaten
Titel
Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma
verfasst von
Eun Kyoung Hong
Seung Hong Choi
Dong Jae Shin
Sang Won Jo
Roh-Eul Yoo
Koung Mi Kang
Tae Jin Yun
Ji-Hoon Kim
Chul-Ho Sohn
Sung-Hye Park
Jae-Kyung Won
Tae Min Kim
Chul-Kee Park
Il Han Kim
Soon Tae Lee
Publikationsdatum
02.05.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 10/2018
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-018-5400-8

Weitere Artikel der Ausgabe 10/2018

European Radiology 10/2018 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.